TABLE 1

Clinical and metabolic characteristics of the patients

Metformin
Rosiglitazone
Placebo
PretreatmentPosttreatmentPretreatmentPosttreatmentPretreatmentPosttreatment
n (M/F)9 (6/3)10 (8/2)11 (9/2)
Age (years)57.7 ± 2.958.2 ± 2.158.6 ± 2.5
BMI (kg/m²)28.8 ± 1.328.0 ± 1.1*28.2 ± 1.028.2 ± 1.229.4 ± 1.329.5 ± 1.3
HbA1c (%)7.1 ± 0.36.4 ± 0.36.8 ± 0.36.4 ± 0.26.3 ± 0.16.2 ± 0.1
Glucose (mmol/l)8.3 ± 0.67.1 ± 0.4*7.0 ± 0.36.8 ± 0.37.2 ± 0.37.5 ± 0.3
Insulin (mU/l)10.8 ± 2.48.4 ± 1.36.8 ± 0.56.4 ± 0.410.2 ± 1.89.8 ± 1.2
C-peptide (nmol/l)0.89 ± 0.120.61 ± 0.07*0.72 ± 0.060.57 ± 0.05*0.83 ± 0.090.71 ± 0.05*
Fasting FFA (μmol/l)458 ± 71496 ± 63596 ± 59552 ± 86598 ± 70511 ± 58
Clamp FFA (μmol/l)145 ± 26102 ± 16*110 ± 1457 ± 5100 ± 2093 ± 19
Total cholesterol (mmol/l)4.2 ± 0.24.4 ± 0.24.9 ± 0.35.5 ± 0.4*4.5 ± 0.34.4 ± 0.3
HDL cholesterol (mmol/l)1.0 ± 0.11.1 ± 0.11.1 ± 0.11.1 ± 0.11.3 ± 0.11.3 ± 0.1
LDL cholesterol (mmol/l)2.6 ± 0.22.5 ± 0.22.9 ± 0.33.7 ± 0.32.7 ± 0.32.7 ± 0.3
Triglycerides (mmol/l)1.4 ± 0.11.5 ± 0.21.8 ± 0.31.5 ± 0.21.1 ± 0.11.0 ± 0.1
Plasma lactate (mmol/l)1.0 ± 0.11.0 ± 0.10.9 ± 0.10.8 ± 0.10.8 ± 0.10.8 ± 0.1
  • Data are means ± SE.

  • *

    * P < 0.05,

  • P < 0.01,

  • P < 0.001 vs. pretreatment.